NCT03510533

Brief Summary

This study should lead to the validation of the concept of the autoAc directed against the neuropeptides involved in food intake regulation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
211

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 4, 2018

Completed
23 days until next milestone

First Posted

Study publicly available on registry

April 27, 2018

Completed
27 days until next milestone

Study Start

First participant enrolled

May 24, 2018

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 13, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 13, 2025

Completed
Last Updated

February 6, 2026

Status Verified

February 1, 2026

Enrollment Period

7.2 years

First QC Date

April 4, 2018

Last Update Submit

February 4, 2026

Conditions

Keywords

autoantibodies (autoAc) circulatingneuropeptides (Ghrelin, l'α-MSH)potential digestive origin

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) involved in food intake regulation among patients with eating disorders

    blood samples collections

    1 week

Secondary Outcomes (3)

  • Scale for determination factors associated with eating disorders

    1 week

  • statute in autoantibody and behavioral characteristics of the eating disorder

    1 week

  • Evaluation of the rate of the autoantibodies directed against bacterial peptide, ClpB among patients presenting with eating disorders

    1 week

Study Arms (2)

Eating disorders patients

EXPERIMENTAL

first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V

Other: Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation

healthy volunteers

OTHER

Volunteers with negative SCOFF test (No active or history of eating disorders)

Other: Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation

Interventions

blood samples (12ml) and stool samples (30g) collections

Also known as: Evaluation of the rate of the autoantibodies directed against bacterial peptide, ClpB, Factors associated with eating disorders
Eating disorders patientshealthy volunteers

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with eating disorders
  • Years and older
  • first clinical visit in nutrition department of CHU de Rouen for eating disorders
  • anorexia nervosa, hyperphagia or bulimia according to the classification DSM-V
  • social security Affiliation
  • Patient who signed the MEC approved informed consent
  • Volunteers
  • Years to 60 Years
  • body mass index ≥ 18,5 kg/m2 and ≤ 24,9 kg/m2
  • negative SCOFF test
  • No active and history of eating disorders
  • social security Affiliation
  • volunteer who signed the MEC approved informed consent

You may not qualify if:

  • Patients with eating disorders
  • No anorexia nervosa, hyperphagia or bulimia according to the classification DSM-V
  • Adults under legal protection or under safeguard of justice or administrative decision
  • Pregnancy
  • Volunteers
  • Active or history of eating disorder
  • Adults under legal protection or under safeguard of justice or administrative decision
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre d'Investigation Clinique

Rouen, 76031, France

Location

MeSH Terms

Conditions

Feeding and Eating Disorders

Interventions

Ghrelinalpha-MSHAppetite RegulationEndopeptidase Clp

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Intervention Hierarchy (Ancestors)

Peptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and ProteinsPro-OpiomelanocortinHypothalamic HormonesMelanocyte-Stimulating HormonesMelanocortinsPituitary Hormones, AnteriorPituitary HormonesNeuropeptidesNerve Tissue ProteinsProteinsNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological PhenomenaAppetiteHungerDigestive System Physiological PhenomenaDigestive System and Oral Physiological PhenomenaATP-Dependent EndopeptidasesATP-Dependent ProteasesATPases Associated with Diverse Cellular ActivitiesAAA ProteinsAcid Anhydride HydrolasesHydrolasesEnzymesEnzymes and CoenzymesAdenosine TriphosphatasesPeptide HydrolasesEndopeptidasesCarrier ProteinsMitochondrial ProteinsChloroplast ProteinsPlant Proteins

Study Officials

  • Najate EL MACHKOURI ACHAMRAH, MD, PhD

    University Hospital, Rouen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Eating disorders compared to healthy volonteers
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2018

First Posted

April 27, 2018

Study Start

May 24, 2018

Primary Completion

August 13, 2025

Study Completion

August 13, 2025

Last Updated

February 6, 2026

Record last verified: 2026-02

Locations